Pemvidutide

Pemvidutide, also known by its research code ALT-801, is a balanced dual agonist peptide that targets both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor with a 1:1 potency ratio. This dual receptor activity distinguishes pemvidutide from selective agonists by engaging complementary pathways implicated in metabolic regulation and liver function. Chemically, pemvidutide has a molecular formula of C182H275N39O54 and a molecular weight of 3873.35 g/mol. It is registered under CAS number 2538014-94-5. The compound’s structure and dual agonist profile reflect its investigational role in metabolic and hepatic disorders.

At Verified Peptides, we recognize that pemvidutide is developed by Altimmune, Inc., a biopharmaceutical company based in Gaithersburg, Maryland. Altimmune is advancing pemvidutide through clinical development primarily for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol use disorder (AUD), two conditions with significant unmet medical needs. The compound remains investigational and has not received FDA approval for any indication.

Regarding regulatory progress, pemvidutide has achieved important milestones that demonstrate its potential therapeutic relevance and expedite its clinical development. It has been granted FDA Fast Track designation for both MASH and AUD, facilitating more frequent communication and review opportunities with regulatory authorities. Additionally, in January 2026, pemvidutide received Breakthrough Therapy Designation specifically for MASH, a status reserved for investigational drugs that show substantial improvement over existing therapies based on preliminary clinical evidence. These designations do not imply approval but reflect recognition of pemvidutide’s promise in addressing complex metabolic liver disease.

Following completion of Phase 2 studies, Altimmune reached alignment with the FDA during an end-of-Phase-2 meeting on the design of a registrational Phase 3 trial, known as PERFORMA. This pivotal trial will enroll patients with moderate-to-advanced liver fibrosis due to MASH and is planned to commence in the second half of 2026. As of this writing, Phase 3 has not yet started, and pemvidutide remains a research compound under investigation.

At Verified Peptides, we supply research-grade pemvidutide for laboratory use, enabling investigators to explore its biochemical properties and mechanistic effects in preclinical and translational research settings. This research-use material is distinct from the pharmaceutical product under clinical development by Altimmune and is intended exclusively for experimental purposes.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Pemvidutide (code ALT-801) is a balanced dual agonist peptide targeting both GLP-1 and glucagon receptors with a 1:1 potency ratio. At Verified Peptides, we recognize pemvidutide as an investigational compound developed by Altimmune, Inc. for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol use disorder (AUD). Its molecular formula is C182H275N39O54, with a molecular weight of 3873.35 g/mol and CAS number 2538014-94-5. While this peptide is under active clinical investigation, it remains unapproved by the FDA, though it has received Fast Track designation for both MASH and AUD, and Breakthrough Therapy Designation for MASH as of January 2026. These regulatory milestones reflect expedited development pathways but do not imply approval or established clinical use.

At Verified Peptides, we highlight two pivotal peer-reviewed clinical trials that have characterized the pharmacodynamic effects of the pharmaceutical formulation of pemvidutide in patients with metabolic steatotic liver disease. The first was a 12-week, randomized, double-blind, placebo-controlled study (PMID 39002641) involving 94 participants with body mass index (BMI) ≥28 kg/m2 and liver fat content (LFC) ≥10% measured by MRI-proton density fat fraction (MRI-PDFF). Participants were randomized equally into four arms receiving once-weekly subcutaneous doses of pemvidutide at 1.2 mg, 1.8 mg, 2.4 mg, or placebo. The study stratified participants by type 2 diabetes status and focused on the primary endpoint of relative percentage reduction in liver fat content at 12 weeks. This trial demonstrated dose-dependent reductions in liver fat, establishing a foundation for longer-term evaluation.

Extending this cohort, the second peer-reviewed trial (PMID 41113119, published in JHEP Reports, June 2025) followed 64 participants for an additional 24 weeks, totaling 36 weeks of treatment exposure. Baseline characteristics included a mean BMI of 36.7 kg/m2 and mean LFC of 22.2%, with 26.6% of participants diagnosed with type 2 diabetes. After 24 weeks, relative reductions in liver fat content from baseline were substantial and dose-dependent: 56.3% at 1.2 mg, 75.2% at 1.8 mg, and 76.4% at 2.4 mg, compared to 14.0% in the placebo group. All active arms showed statistically significant improvements over placebo (p<0.001). This extension trial reinforced the sustained efficacy of pemvidutide in reducing hepatic steatosis over a clinically relevant timeframe.

In addition to these peer-reviewed studies, At Verified Peptides note the topline results from the IMPACT Phase 2b trial in MASH, announced by Altimmune in December 2025 and presented at the European Association for the Study of the Liver (EASL) Congress in May 2026. This 48-week study evaluated pemvidutide’s effects on non-invasive fibrosis markers, including the Enhanced Liver Fibrosis (ELF) score and Liver Stiffness Measurement (LSM). The topline data demonstrated statistically significant improvements versus placebo in these fibrosis markers, alongside continued weight loss at the 1.8 mg dose without evidence of a weight-loss plateau. Safety and tolerability profiles remained consistent with earlier trials. These topline findings, while not yet peer-reviewed, provide important insights into pemvidutide’s potential impact on liver fibrosis progression and metabolic parameters.

At Verified Peptides, we emphasize that all these clinical investigations utilized the pharmaceutical formulation developed by Altimmune. Our research-grade pemvidutide material is distinct and intended solely for laboratory research purposes to facilitate investigation of the dual GLP-1/glucagon receptor mechanism in vitro and in vivo models. Researchers can access the clinical trial data and regulatory information through PubMed and NIH resources for further study design and contextual understanding.

Preclinical evidence supporting pemvidutide’s mechanism includes translational mouse models of nonalcoholic steatohepatitis (NASH), where the dual receptor agonism demonstrated relevant biological effects on liver disease parameters (PMID 35461369). This foundational research informed subsequent clinical development and continues to support mechanistic exploration using research-grade peptide material.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Pemvidutide (code ALT-801) is distinguished by its balanced 1:1 potency ratio as a dual agonist for the GLP-1 receptor and glucagon receptor. At Verified Peptides, we recognize this deliberate design choice sets pemvidutide apart from other dual agonists that often exhibit skewed receptor activity favoring one receptor over the other. This balanced receptor engagement is hypothesized to optimize the therapeutic profile by leveraging the complementary metabolic effects of both GLP-1 and glucagon pathways in a synergistic manner. Such balance may contribute to the compound’s observed efficacy in reducing liver fat content and improving fibrosis markers in metabolic dysfunction-associated steatohepatitis (MASH), as well as its benefits in related metabolic conditions.

Before entering human clinical trials, pemvidutide’s mechanism of action was supported by preclinical evidence from a mouse translational model of nonalcoholic steatohepatitis (NASH). This earlier research, published under the designation ALT-801 (PMID 35461369), demonstrated the relevance of dual GLP-1/glucagon receptor activation in ameliorating liver disease pathology. At Verified Peptides, we emphasize this preclinical foundation as a critical step that informed the subsequent clinical development strategy, providing proof-of-concept data that helped justify advancing pemvidutide into human studies.

Another notable aspect of pemvidutide’s research profile is its investigation across multiple distinct indications. At Verified Peptides, we highlight that pemvidutide is currently under study not only for MASH but also for obesity and alcohol use disorder (AUD). This breadth of investigation reflects the peptide’s multifaceted metabolic effects and the therapeutic potential of dual receptor agonism beyond a single disease state. The FDA has granted pemvidutide Fast Track designation for both MASH and AUD, as well as Breakthrough Therapy Designation for MASH, underscoring the regulatory recognition of its potential across these diverse indications. Although Phase 3 trials have not yet commenced, the planned registrational trial for MASH patients with moderate-to-advanced fibrosis represents a critical next step in evaluating pemvidutide’s clinical utility.

At Verified Peptides, we supply research-grade pemvidutide for laboratory investigation, enabling researchers to explore its pharmacological properties, receptor interactions, and potential applications in metabolic and liver disease models. This availability supports ongoing efforts to elucidate the compound’s mechanisms and optimize its development as a dual GLP-1/glucagon receptor agonist.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

At Verified Peptides, we prioritize the highest standards of quality and reliability for research-grade pemvidutide, recognizing its investigational status and the critical need for rigorous characterization in laboratory settings. Research-grade pemvidutide, distinct from the pharmaceutical formulation under development by Altimmune, Inc., is supplied exclusively for research use and is not intended for human consumption or clinical application. To ensure purity and identity, we implement comprehensive quality assurance protocols including third-party Certificates of Analysis (COA) that verify batch-to-batch consistency.

Each batch of pemvidutide undergoes stringent high-performance liquid chromatography (HPLC) purity testing to confirm that the peptide meets or exceeds established purity thresholds, typically above 95%. This testing is essential to exclude impurities or degradation products that could confound experimental results. Additionally, we employ mass spectrometry to unequivocally confirm the molecular identity of pemvidutide, verifying the molecular formula C182H275N39O54 and molecular weight of 3873.35 g/mol, consistent with the CAS number 2538014-94-5. This dual analytical approach ensures that researchers receive a peptide that aligns with the expected chemical profile of the investigational dual GLP-1/glucagon receptor agonist ALT-801.

At Verified Peptides, we understand the importance of reliable, well-characterized research compounds in advancing the study of metabolic dysfunction-associated steatohepatitis (MASH) and related conditions. Our commitment to transparency and rigorous testing supports reproducibility and confidence in experimental outcomes. By maintaining strict quality controls and providing detailed analytical documentation, we enable researchers to investigate pemvidutide’s pharmacological properties and potential mechanisms without ambiguity regarding compound integrity.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

At Verified Peptides, we recommend that research-grade pemvidutide, supplied as a lyophilized powder, be stored under conditions optimized for peptide stability to preserve its integrity for laboratory use. Lyophilized pemvidutide should be kept refrigerated at 2–8°C or frozen at –20°C to –80°C for longer-term storage. Avoid exposure to moisture and repeated freeze-thaw cycles, as these can degrade peptide quality and reduce experimental reproducibility. Upon reconstitution, typically performed with sterile water or an appropriate buffer, pemvidutide solutions should be used promptly or aliquoted and stored at –20°C to –80°C to minimize degradation. Solutions are generally less stable than the lyophilized form and should not be subjected to multiple freeze-thaw events. Shelf-life of lyophilized pemvidutide depends on storage conditions but is commonly stable for months to a year when maintained properly in a desiccated environment. Researchers should monitor for any changes in appearance, such as discoloration or precipitation, which may indicate peptide degradation. Handling pemvidutide under inert atmosphere or low-light conditions can further protect against oxidative damage. These precautions ensure that pemvidutide retains its biochemical properties for reliable use in in vitro or in vivo experimental models investigating its dual GLP-1/glucagon receptor agonist activity.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.